

| | | | |
|---|-----------|---|-----------|
| Scientific Notes | 3 | General Information | 67 |
| Collaborative study to assess the reproducibility of a reverse-phase LC method to determine the content and to estimate the impurities of benzathine benzylpenicillin | 3 | CD-ROM 2000 of the European Pharmacopoeia | 67 |
| System suitability criteria a case study: the determination of impurities in dicloxacillin sodium | 8 | <i>Press release: Conference in Berlin</i> | 68 |
| Inter-laboratory trials to assess a validation procedure for volumetric titrations | 18 | Conditions of sale of CRS | 69 |
| | | List of CRS adopted in November 1999 | 70 |
| | | Prepublication brochure (June 1999) | 72 |
| | | List of texts published in the June 1999 prepublication brochure | 73 |
| | | List of texts adopted in November 1999 | 74 |
| Readers' Tribune | 26 | Draft monographs for comment | 79 |
| Near IR spectrometry | 26 | Arnica tincture | 84 |
| | | Assay of human coagulation factor II (2.7...) | 80 |
| Enquiry | 27 | Assay of human coagulation factor X (2.7...) | 81 |
| Alkyl mesilate (methanesulphonate) impurities in mesilate salts | 27 | Azaperone | 144 |
| | | Bovine viral diarrhoea vaccine (inactivated) | 97 |
| | | Canine adenovirus vaccine (live) | 102 |
| | | Caraway oil | 92 |
| | | Carbon dioxide | 103 |
| | | Cetyl palmitate | 125 |
| | | Dihydroergocristine mesilate | 155 |
| Certification of Suitability of the Monographs of the Ph. Eur. | 28 | Diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed) | 126 |
| List of certificates issued by the EDQM | 28 | Diphtheria, tetanus, pertussis (acellular, component) and haemophilus type b conjugate vaccine (adsorbed) | 95 |
| | | Diphtheria, tetanus, pertussis (acellular, component) and hepatitis B (rDNA) vaccine (adsorbed) | 129 |
| | | Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed) | 107 |
| | | Framycetin sulphate | 116 |
| | | Gemfibrozil | 170 |
| | | Greater celandine | 161 |
| | | Heptaminol hydrochloride | 138 |
| | | Human coagulation factor VII, freeze-dried | 80 |
| | | Human plasma (pooled and treated for virus inactivation) | 168 |
| | | Human prothrombin complex, freeze-dried | 79 |
| | | Hymecromone | 157 |
| | | Ibuprofen | 148 |
| | | Iodinated (¹²⁵ I) human albumin injection | 110 |
| | | Ioxaglic acid | 141 |
| | | Java tea | 87 |
| | | Levamisole | 153 |
| | | Levamisole hydrochloride | 150 |
| | | Lobeline hydrochloride | 140 |
| | | Marsh mallow leaf | 167 |
| | | Mesterolone | 146 |
| | | Mint oil, dementholised | 88 |
| | | Neomycin sulphate | 119 |
| | | Netilmicin sulphate | 122 |
| | | Nitrous oxide | 105 |
| | | Oak bark | 162 |
| | | Orphenadrine citrate | 137 |
| | | Orphenadrine hydrochloride | 135 |
| | | Phytosterol | 165 |
| | | Pipemidic acid trihydrate | 133 |
| | | Poloxamers | 172 |
| | | Pravastatin sodium | 114 |
| | | Rosemary oil | 99 |
| | | Sage leaf (<i>salvia officinalis</i>) | 163 |
| | | Semi-solid preparations for cutaneous application | 112 |
| | | Sodium perborate trihydrate | 126 |
| | | Star anise | 164 |
| | | Thyme | 82 |
| | | Wild pansy (flowering aerial parts) | 90 |
| | | Zinc stearate | 159 |
| Official Announcement - Rapid Implementation on 01/01/2000 | 45 | | |
| Magnesium stearate | 45 | | |
| Isopropyl alcohol | 47 | | |
| Products with risk of transmitting agents of animal spongiform encephalopathies | 48 | | |
| Minimising the risk of transmitting animal spongiform encephalopathy agents via medicinal products (5.2.8) | 48 | | |
| <i>Replacement Production statements for monographs on TSE-risk products</i> | 52 | | |
| Aprotinin | 52 | | |
| Aprotinin concentrated solution | 52 | | |
| Calcium stearate | 52 | | |
| Cholesterol | 52 | | |
| Chymotrypsin | 52 | | |
| Decyl oleate | 53 | | |
| Diethylene glycol monopalmitostearate | 53 | | |
| Erythromycin stearate | 53 | | |
| Ethyl oleate | 53 | | |
| Ethylene glycol monopalmitostearate | 53 | | |
| Glycerol distearate | 53 | | |
| Glycerol mono-oleates | 53 | | |
| Glycerol monostearate 40-55 | 53 | | |
| Hyaluronidase | 53 | | |
| Insulin | 53 | | |
| Macrogol stearate | 53 | | |
| Macrogol stearyl ether | 53 | | |
| Magnesium stearate | 53 | | |
| Parnaparin sodium | 53 | | |
| Propylene glycol monopalmitostearate | 53 | | |
| Stearic acid | 53 | | |
| Stearoyl macrogolglycerides | 53 | | |
| Trypsin | 53 | | |
| Vaccines for human use | 53 | | |
| International Conferences | 55 | | |
| Mycoplasma Testing the Potentialities & Roles of PCR Tests - 13-14 March 2000, Paris, France | 55 | | |
| The Future Face of the European Pharmacopoeia Current Concerns in Pharmaceutical Analysis 9-10 October 2000, Lisbon, Portugal | 59 | | |
| Tetanus Vaccines for Human Use 22-23 June 2000, Strasbourg, France | 63 | | |

THE EUROPEAN PHARMACOPOEIA

Paper Version

3rd Edition 1997 + Supplement 2000

Price : 456 Euro (Europe)
509 Euro (Outside Europe)

Supplement 2000

Price : 140 Euro (Europe)
170 Euro (Outside Europe)

— PHARMEUROPA — SPECIAL ISSUE —

“List of Standard Terms” 2000 Edition

The present List of Standard Terms is a revised List of Standard Terms which was drawn up in response to a request from the European Commission. It covers both medicines for human and veterinary use. Those Standard Terms are to be used in answering the questions 2, 2.1 and 2.2 of part IA and sections 3 and 6.5 of part IB (Summary of the Product Characteristics) of the EU application format.

The current issue of Standard Terms is composed of :

— an Introduction :

- a section of general principles and instructions for the use of Standard Terms,
- the summary of the changes (amendments, additions, deletions) performed since the last publication (February 1998),
- procedure for the addition, deletion or modification of terms in the list of Standard Terms,

— three lists of standard terms :

- list of pharmaceutical forms,
- list of routes and/or methods of administration,
- list of containers, closures and administration devices.

The previous edition contained translations in sixteen European languages : Croatian, Danish, Dutch, English, Finnish, French, German, Greek, Italian, Norwegian, Portuguese, Slovak, Slovenian, Spanish, Swedish and Turkish). The present lists have further been enlarged by adding the Bulgarian, Czech, Hungarian, Icelandic and Polish Terms.

Price: 38 Euro (Europe) - 42 Euro (Outside Europe) .

Information and orders:

Council of Europe
European Department for the Quality of Medicines (EDQM)
BP 907 - F67029 Strasbourg Cedex 1
tel. : +33 (0)3 88 41 20 36 - fax : + 33 (0)3 88 41 27 71
E-mail : pub@ pheur.org

tifically sound rationale be used when building libraries and or calibrations. This rationale may vary depending on the application and products For example, in a quantitative calibration, correlation may not be a good indicator of performance, particularly when the calibration range is small and the error associated with primary method is comparatively large.

- Based on the definition of the identity test, NIR can be used for identification of mixtures. Depending on the requirements of the application, as long as the

method is shown to be sensitive to significant changes in composition (selectivity - this may be difficult when concentrations are low), along with the other validation requirements, it should be considered acceptable. For example, if distinction between two different dosage strengths of a single product in tablet form is required, one should be able to use NIR for this purpose if the method is shown to be validatable and thus sensitive to the differences in composition. Therefore we do not believe that discussions should focus on the identification of single active ingredients or excipients.

Enquiry

ALKYL MESILATE (METHANESULPHONATE) IMPURITIES IN MESILATE SALTS

The need for limits on methyl, ethyl and isopropyl mesilate esters in active substances presented as mesilates has recently been discussed by the European Pharmacopoeia Commission. These esters are highly toxic and assurance is needed that they are not present in unacceptable quantities in medicinal products. However, they are also very reactive and it is therefore possible that in practice the level of contamination is negligible. Readers of Pharmeuropa are asked to inform EDQM of their opinion on the need for a test and limit in the light of their experience with mesilate salts. Information on analytical methods and the level of such impurities found in practice would be extremely valuable. Seven monographs on mesilates are at present included in the European Pharmacopoeia and would be concerned if a test and limit were to be added:

Betahistine mesilate
Bromocriptine mesilate
Deferoxamine mesilate
Dihydroergocristine mesilate
Dihydroergotamine mesilate
Pefloxacin mesilate dihydrate
Phentolamine mesilate

Please send your replies to:

Council of Europe
European Directorate for the Quality of Medicines
B.P. 907
67029 Strasbourg Cedex 1
France
Fax: + 33 (0)3 88 41 27 71.
E-mail: info@pheur.org.